Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases, and Amyotrophic Lateral Sclerosis Research.
Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach
Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease
The clinical relevance of <scp>MOG</scp> antibody testing in cerebrospinal fluid
Locus for severity implicates CNS resilience in progression of multiple sclerosis
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
Higher dietary quality is prospectively associated with lower MRI FLAIR lesion volume, but not with hazard of relapse, change in disability or black hole volume in people with Multiple Sclerosis
Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Associations between diet quality and depression, anxiety, and fatigue in multiple sclerosis
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
The COVID-19 pandemic and the use of MS disease-modifying therapies
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Incidence and prevalence of NMOSD in Australia and New Zealand
Defining secondary progressive multiple sclerosis
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
Contribution of different relapse phenotypes to disability in multiple sclerosis
Defining reliable disability outcomes in multiple sclerosis
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis